Security
RMD · RESMED INC
RMDNYSECommon stockCurrentCIK 943819Updated Sep 27, 2026
RMD price & chart
Loading TradingView…
NYSE:RMD on TradingView ↗About the company
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.
In the news
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference ↗
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) ↗
Recent filings
144 filing
144 filing
Other Events
Items 8.01
Changes in Registrant's Certifying Accountant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 4.01, 5.02, 7.01, 9.01
10-K filing
Show 5 more recent filings
SCHEDULE 13G filing
144 filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
144 filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,965,950,000Source | 8,174,391,000Source | 6,872,394,000Source | 6,751,708,000Source |
| Property, Plant and Equipment, NetUSD | 581,829,000Source | 550,790,000Source | 548,025,000Source | 537,856,000Source |
| GoodwillUSD | 2,909,575,000Source | 3,046,680,000Source | 2,842,055,000Source | 2,770,299,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,469,234,000Source | 1,209,450,000Source | 238,361,000Source | 227,891,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,036,233,000Source | 939,492,000Source | 837,275,000Source | 704,909,000Source |
| Inventory, NetUSD | 945,805,000Source | 927,711,000Source | 822,250,000Source | 998,012,000Source |
| Assets, CurrentUSD | 4,324,739,000Source | 3,505,605,000Source | 2,357,719,000Source | 2,367,830,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 416,081,000Source | 428,952,000Source | 459,833,000Source | 437,018,000Source |
| Operating Lease, Right-of-Use AssetUSD | 153,167,000Source | 167,497,000Source | 151,121,000Source | 127,955,000Source |
| Other Assets, NoncurrentUSD | 214,649,000Source | 185,839,000Source | 284,001,000Source | 262,453,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,380,557,000Source | 2,206,532,000Source | 2,008,351,000Source | 2,621,805,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | 7,255,121,000Source | 6,081,490,000Source | 4,991,647,000Source | 4,253,016,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -82,515,000Source | -74,699,000Source | -251,529,000Source | -272,528,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,585,393,000Source | 5,967,859,000Source | 4,864,043,000Source | 4,129,903,000Source |
| Additional Paid in Capital, Common StockUSD | 2,190,614,000Source | 2,033,599,000Source | 1,896,604,000Source | 1,772,083,000Source |
| Liabilities and EquityUSD | 8,965,950,000Source | 8,174,391,000Source | 6,872,394,000Source | 6,751,708,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,395,110,000Source | 1,019,120,000Source | 910,655,000Source | 758,533,000Source |
| Operating Lease, Liability, CurrentUSD | 29,141,000Source | 30,506,000Source | 25,278,000Source | 21,919,000Source |
| Accounts Payable, CurrentUSD | 308,923,000Source | 278,157,000Source | 237,728,000Source | 150,756,000Source |
| Operating Lease, Liability, NoncurrentUSD | 137,413,000Source | 153,015,000Source | 141,444,000Source | 116,853,000Source |
| Other Liabilities, NoncurrentUSD | 213,028,000Source | 141,520,000Source | 42,257,000Source | 68,166,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 494,921,000Source | 402,253,000Source | 377,678,000Source | 365,660,000Source |
| Deferred Tax Liabilities, NetUSD | 242,933,000Source | 219,839,000Source | 223,098,000Source | 231,221,000Source |
| Long-term DebtUSD | 399,415,000Source | 658,392,000Source | 697,313,000Source | 1,431,234,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 201,342,000Source | 198,473,000Source | 176,870,000Source | 165,156,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 104,348,000Source | 91,661,000Source | 80,184,000Source | 71,142,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 96,778,000Source | 76,684,000Source | 134,278,000Source | 106,511,000Source |
| Increase (Decrease) in InventoriesUSD | 9,920,000Source | 80,165,000Source | -172,203,000Source | 248,833,000Source |
| Deferred Income Tax Expense (Benefit)USD | 3,881,000Source | -60,990,000Source | -49,878,000Source | -45,432,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,805,829,000Source | 1,751,588,000Source | 1,401,260,000Source | 693,299,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 350,724,000Source | 139,248,000Source | 133,464,000Source | 1,012,749,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -545,199,000Source | -200,045,000Source | -269,784,000Source | -1,159,845,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 156,285,000Source | 89,865,000Source | 99,460,000Source | 119,672,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 21,833,000Source | 18,077,000Source | 8,757,000Source | 30,631,000Source |
| Payments for Repurchase of Common StockUSD | 700,037,000Source | 300,025,000Source | 150,011,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,007,029,000Source | -606,253,000Source | -1,119,287,000Source | 422,874,000Source |
| Dividends paid | — | — | — | — |
| Repayments of Long-term DebtUSD | 10,000,000Source | 40,000,000Source | 835,000,000Source | 405,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 259,784,000Source | 971,089,000Source | 10,470,000Source | -45,819,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,469,234,000Source | 1,209,450,000Source | 238,361,000Source | 227,891,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 27,057,000Source | 28,415,000Source | 45,708,000Source | 47,379,000Source |
| Income Taxes Paid, NetUSD | 357,167,000Source | 214,013,000Source | 278,400,000Source | 216,866,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,183,000Source | 25,799,000Source | -1,719,000Source | -2,147,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 104,348,000Source | 91,661,000Source | 80,184,000Source | 71,142,000Source |
| Amortization of Intangible AssetsUSD | 31,779,000Source | 32,116,000Source | 32,963,000Source | 30,396,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | -10,299,000Source | -4,045,000Source | — |
| DepreciationUSD | 103,000,000Source | 111,800,000Source | 88,900,000Source | 84,700,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 7,409,000Source | 11,742,000Source | 4,963,000Source | — |
| Equity Securities, FV-NI, Gain (Loss)USD | -15,014,000Source | -10,299,000Source | -4,045,000Source | 9,922,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | 389,000Source | — | 3,937,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | -15,000,000Source | -10,700,000Source | -4,000,000Source | 6,000,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | -9,922,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | 4,353,000Source | — | — | — |
| GoodwillUSD | 2,909,575,000Source | 3,046,680,000Source | 2,842,055,000Source | 2,770,299,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | 6,955,000Source | 3,644,000Source | -1,848,000Source | -7,265,000Source |
| Income (Loss) from Equity Method Investments, Net of Dividends or DistributionsUSD | 2,382,000Source | 3,644,000Source | -1,848,000Source | — |
| Income Tax Expense (Benefit)USD | 396,123,000Source | 276,843,000Source | 243,847,000Source | 204,108,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -10,721,000Source | 1,054,000Source | -1,397,000Source | -1,735,000Source |
| Net Income (Loss) Attributable to ParentUSD | 1,523,293,000Source | 1,400,723,000Source | 1,020,951,000Source | 897,556,000Source |
| Nonoperating Income (Expense)USD | 32,701,000Source | -7,797,000Source | -55,095,000Source | -30,207,000Source |
| Operating ExpensesUSD | 1,565,024,000Source | 1,369,607,000Source | 1,335,410,000Source | 1,223,791,000Source |
| Other Nonoperating Income (Expense)USD | -9,154,000Source | -5,256,000Source | -3,494,000Source | -5,712,000Source |
| Payments to Acquire InvestmentsUSD | 28,536,000Source | 6,416,000Source | 12,765,000Source | 32,229,000Source |
| Proceeds from Issuance of Common StockUSD | 74,503,000Source | 74,439,000Source | 53,094,000Source | 49,142,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 0Source | 105,000,000Source | 1,070,000,000Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | 5,653,443,000Source | 5,146,327,000Source | 4,685,297,000Source | 4,222,993,000Source |
| Cost of RevenueUSD | 2,201,704,000Source | 2,091,357,000Source | 2,029,994,000Source | 1,867,331,000Source |
| Selling, General and Administrative ExpenseUSD | 1,119,528,000Source | 991,019,000Source | 917,136,000Source | 874,003,000Source |
| Operating Income (Loss)USD | 1,886,715,000Source | 1,685,363,000Source | 1,319,893,000Source | 1,131,871,000Source |
| Other Nonoperating Income (Expense)USD | -9,154,000Source | -5,256,000Source | -3,494,000Source | -5,712,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,919,416,000Source | 1,677,566,000Source | 1,264,798,000Source | 1,101,664,000Source |
| Income Tax Expense (Benefit)USD | 396,123,000Source | 276,843,000Source | 243,847,000Source | 204,108,000Source |
| Net Income (Loss) Attributable to ParentUSD | 1,523,293,000Source | 1,400,723,000Source | 1,020,951,000Source | 897,556,000Source |
| Earnings Per Share, BasicUSD per share | 10.47Source | 9.55Source | 6.94Source | 6.12Source |
| Earnings Per Share, DilutedUSD per share | 10.43Source | 9.51Source | 6.92Source | 6.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 145,523,000Source | 146,716,000Source | 147,021,000Source | 146,765,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 146,054,000Source | 147,340,000Source | 147,550,000Source | 147,455,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 31,779,000Source | 32,116,000Source | 32,963,000Source | 30,396,000Source |
| Business Combination, Acquisition Related CostsUSD | — | 2,031,000Source | 0Source | 10,949,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 2.4Source | 2.12Source | 1.92Source | 1.76Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | 2,169,925,000Source | 2,059,241,000Source | 1,997,031,000Source | 1,836,935,000Source |
| Current Income Tax Expense (Benefit)USD | 392,242,000Source | 337,833,000Source | 293,725,000Source | 249,540,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | -10,299,000Source | -4,045,000Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | 389,000Source | — | 3,937,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | -9,922,000Source |
| Gross ProfitUSD | 3,451,739,000Source | 3,054,970,000Source | 2,655,303,000Source | 2,355,662,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 597,342,000Source | 359,741,000Source | 181,107,000Source | 128,589,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 6,955,000Source | 3,644,000Source | -1,848,000Source | -7,265,000Source |
| Interest Income (Expense), NetUSD | — | — | — | -47,379,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 49,914,000Source | 4,114,000Source | -45,708,000Source | — |
| Nonoperating Income (Expense)USD | 32,701,000Source | -7,797,000Source | -55,095,000Source | -30,207,000Source |
| Operating ExpensesUSD | 1,565,024,000Source | 1,369,607,000Source | 1,335,410,000Source | 1,223,791,000Source |
| Research and Development ExpenseUSD | 378,285,000Source | 331,284,000Source | 307,525,000Source | 287,642,000Source |
Filing attachments
d292919dex991.htm · 8-K · 2026-08-17
EX-99.1 3 d292919dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor Nominating and Governance Chair Carol Burt to become Lead Director. Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug.17, 2026 - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announ…
Read attachment ↗d158732dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d158732dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1…
Read attachment ↗d88958dex991.htm · 8-K · 2026-07-07
EX-99.1 2 d88958dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Resmed Announces Agreement to Sell MatrixCare Business Sharpens Resmed’s focus on high-growth sleep and connected care markets SAN DIEGO, July 7, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equit…
Read attachment ↗d50610dex991.htm · 8-K · 2026-04-30
EX-99.1 2 d50610dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For Investors For Media Salli Schwartz Brad Lotterman Salli. Schwartz@resmed.com Brad.lotterman@resmed.com investorrelations@resmed.com news@resmed.com Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on slee…
Read attachment ↗d146862dex991.htm · 8-K · 2026-04-30
EX-99.1 2 d146862dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%; no…
Read attachment ↗d80310dex991.htm · 8-K · 2026-01-29
EX-99.1 2 d80310dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For investors For media +1 858-221-3304 +1 619-510-1281 investorrelations@resmed.com news@resmed.com Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% Income from operations increased 18%; non-GAAP inc…
Read attachment ↗